Search - tctmd.com

Displaying 61 - 80 of 285

Sort: Relevancy | Date

Presentation TCT 2018

TCT-62: Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Patrick W. Serruys

September 21, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

Presentation ESC 2018

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Presenter: Robert Byrne

August 29, 2018

Presentation ESC 2018

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

Presenter: Holger M. Nef

August 29, 2018

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

Podcast TCTMD Talking Points

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

August 22, 2018

News Conference News EuroPCR 2018

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Michael O'Riordan

May 25, 2018

News Conference News EuroPCR 2018

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Shelley Wood

May 24, 2018

News Industry News

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

May 24, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

Podcast

CrossBoss First, New ABSORB Data, Radiation Worries, and More

April 11, 2018

News Industry News

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

March 21, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

Presentation JIM 2018

New Fully Absorbable Patch Based Large Hole Vascular Closure Device

Presenter: Michael Laule

February 23, 2018

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

Presenter: Martin B. Leon, Marco Valgimigli, Giulio G. Stefanini

November 01, 2017

Advertisement

TCT-62: Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

ISAR-Absorb MI: A Prospective, Randomized Trial of BVS vs EES in Patients Undergoing Coronary Stenting for Myocardial Infarction

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

CrossBoss First, New ABSORB Data, Radiation Worries, and More

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

New Fully Absorbable Patch Based Large Hole Vascular Closure Device

Positive Five-Year Data Published for MiStent in EuroIntervention

The Biggest News of 2017: TCTMD’s Top 10

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

TCTMD’s Top 10 Most Popular Stories for November 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content